Healthy lifestyle, Agent Orange exposure, and inherited PCa risk: An analysis of the Million Veteran Program

Meghana S. Pagadala, PhD[1,2,3,*]
Asona Lui, MD, PhD[4,*]
Julie Lynch, PhD, RN, MBA[5,6]
Roshan Karunamuni, PhD[4]
Kyung Min Lee, PhD[5,6]
Anna Plym, PhDU[7,8,9]
Brent S. Rose, MD[1,4]
Hannah Carter, PhD[10]
Adam S. Kibel, MD[7]
Scott L. DuVall, PhD[5,6]
J. Michael Gaziano, MD, MPH[11,12]
Matthew S. Panizzon, PhD[1,13]
Richard L. Hauger, MD[1,13,14]
Tyler M. Seibert, MD, PhD[1,4,15,16, #]

[1] Research Service, VA San Diego Healthcare System, San Diego, CA

[2] Medical Scientist Training Program, University of California San Diego, La Jolla, CA

[3] Biomedical Science Program, University of California San Diego, La Jolla, CA

[4] Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA

[5] VA Informatics and Computing Infrastructure, VA Salt Lake City Healthcare System (VINCI), Salt Lake City, UT

[6] Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT

[7] Division of Urologic Surgery, Brigham and Women's Hospital, Boston, MA

[8] Epidemiology, TH Chan School of Public Health, Harvard University, Boston, MA

[9] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

[10] Department of Medicine, University of California San Diego, La Jolla, CA

[11] Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA

[12] Department of Medicine, Brigham and Women's Hospital, Boston, MA

[13] Center for Behavioral Genetics of Aging, University of California San Diego, La Jolla, CA

[14] Center of Excellence for Stress and Mental Health (CESAMH), VA San Diego Healthcare System, San Diego, CA

[15] Department of Radiology, University of California San Diego, La Jolla, CA

[16] Department of Bioengineering, University of California San Diego, La Jolla, CA

* These authors contributed equally to the manuscript

Corresponding author

Abstract

Background: Prostate cancer (PCa) risk is understood to be mostly unmodifiable and inherited, but there is evidence that environmental and behavioral factors may also contribute. A recent study of health professional cohorts suggest a healthy lifestyle can mitigate a high inherited risk of lethal PCa. It is unknown how modifiable factors affect PCa risk in more diverse populations.

Objective: To determine the effects of healthy lifestyle and Agent Orange exposure on PCa risk when accounting for race/ethnicity, family history, and genetic risk in a diverse population.

Design, Setting, and Participants: The Million Veteran Program (MVP) is a national, population-based cohort study of United States military veterans conducted 2011-2021 with 590,750 male participants available for analysis. Healthy lifestyle was quantified as: A healthy lifestyle score (range 0-3) was calculated with a point assigned for each of the following at MVP enrollment: not a current smoker, body mass index (BMI) ≤30 and strenuous activity ≥2 days per week. Agent Orange exposure was obtained from VA records. Genetic risk was assessed via a polygenic hazard score using genotype data.

Outcome Measurements and Statistical Analysis: Age at diagnosis of PCa, diagnosis of metastatic PCa, and death from PCa were assessed via Cox proportional hazards models.

Results and Limitations: Healthy lifestyle was independently associated with reduced metastatic PCa (HR 0.82, 95% CI 0.77–0.87, $p<0.001$) and fatal PCa (HR 0.76, 95% CI 0.68–0.86, $p<0.01$) when accounting for family history, genetic risk, and race/ethnicity. The benefit of healthy lifestyle was also observed in Black participants on subset analysis. Agent Orange exposure was an independent factor for PCa diagnosis (HR 1.06, 95% CI 1.04-1.09).

Conclusions: Adherence to a healthy lifestyle is associated with reduced risk of metastatic or fatal PCa, which offsets inherited risk.

Patient Summary: In a study of US military veterans, we studied whether men with a healthy lifestyle (not smoking, frequent exercise, and healthy weight) had lower risk of prostate cancer, when accounting for race/ethnicity, family history, and genetic risk. We found that healthy lifestyle was associated with lower risk of metastatic or fatal cancer.

Introduction

Prostate cancer (PCa) risk is understood to be mostly inherited and not modifiable. The strongest known risk factors are age, race/ethnicity (especially Black race), family history, and specific genetic elements.[1-7] However, there is growing evidence of modifiable PCa risk factors, including environmental elements and behavior.[8] Meta-analyses of observational studies have identified an association between tobacco use, low physical activity, and obesity with increased risk of PCa progression and PCa-related death.[8-11] Additionally, exposure to Agent Orange (a mixture of herbicides that contains dioxin, a known carcinogen) has been reported to increase PCa risk among US Vietnam War veterans.[12,13] Specific dietary factors have also been linked to increased risk of PCa or PCa progression.[14,15]

An intriguing recent study of two cohorts of health professionals suggested a healthy lifestyle can mitigate a high inherited risk of lethal PCa.[16] Healthy lifestyle, including regular exercise and a wholesome diet (low in saturated fats but high in fruits, vegetables, low-fat dairy and fish) is also known to reduce the risks of cardiovascular disease, colorectal cancer, and breast cancer.[17-19] However, it is not known whether the protective effect of a healthy lifestyle on PCa risk holds true for more diverse populations, especially when accounting for race/ethnicity and family history.

We investigated the association of modifiable lifestyle and environmental factors on PCa risk in a diverse population when accounting for common major inherited risk factors: race/ethnicity, family history, and genetic risk. We used data from the Department of Veteran Affairs (VA) Million Veteran Program (MVP), a population-based cohort with genotyping, long-term follow-up, and linked clinical records for over 870,000 participating US veterans. The MVP is one of the largest and most diverse electronic health record-linked biobanks in the world, with a unique structure that allows for detailed investigation into the interactions between inherited risk, lifestyle, and Agent Orange exposure.[20] We tested a healthy lifestyle score and Agent Orange exposure for associations with age at PCa diagnosis, age at diagnosis of PCa metastasis, and lifetime PCa-specific mortality.

Methods

Participants

We obtained data from MVP for individuals recruited from 63 Veterans Affairs Medical Centers across the United States (US) beginning in 2011. All veterans were eligible for participation in MVP. Study participation included consenting to access the participant's electronic health records for research purposes. The MVP received ethical and study protocol approval from the VA Central Institutional Review Board in accordance with the principles outlined in the Declaration of Helsinki. Only men were included in this PCa study. Participant characteristics are shown in **Table 1**.

Healthy lifestyle score (HLS)

281,923 of the 590,750 MVP participants completed a questionnaire with nearly 400 detailed behavioral and diet questions. We calculated a healthy lifestyle score (HLS) similar to

those reported in previous studies[16,17] and with a range from 0 to 3, with a point assigned for each of the following: not a current smoker, healthy weight (body mass index [BMI] ≤30) and strenuous physical activity ≥2 days per week. BMI was calculated from the participants' baseline height and weight obtained at time of enrollment in MVP.

Agent Orange exposure

Exposure to Agent Orange was determined by the VA Compensation & Pension Committee, as recorded in the MVP data core. We limited analyses of Agent Orange exposure in the present study to those who were on active duty during the Vietnam War era (1955-1975).

Clinical data extraction

Comprehensive description of clinical endpoints used for PCa Cox proportional hazards analysis were described previously.[21] Briefly, PCa diagnosis, age at diagnosis, and date of last follow-up were retrieved from the VA Corporate Data Warehouse based on ICD codes and VA Central Cancer Registry data. Age at diagnosis of metastatic PCa indicated the age of the participant when diagnosed with either nodal or distant metastases as determined through a validated natural language processing tool.[27] Fatal PCa information was determined from National Death Index. Participants with ICD10 code "C61" as underlying cause of death were considered to have died from PCa. Family history was recorded as either the presence or absence of (one or more) first-degree relatives with PCa.

Genetic risk: polygenic hazard score (PHS290)

Blood sampling and DNA extraction were conducted by MVP as described previously.[1,22] The MVP 1.0 genotyping array contains a total of 723,305 variants, enriched for low frequency variants in African and Hispanic populations and variants associated with diseases common to the VA population.[25] Details on quality control and imputation have been described previously.[22]

To assess genetic risk, we calculated a previously developed and validated polygenic hazard score using 290 common genetic variants (PHS290) that reliably stratifies men for age-dependent genetic risk of PCa and is associated with PCa, metastatic PCa, and PCa death.[5] Details of PHS290 calculation in MVP are described elsewhere. [1,5,21] PHS290 performs well in diverse datasets and is independently associated with PCa risk.[1,5,21]

Cox proportional hazards analysis

We used Cox proportional hazards models to evaluate the association of HLS and Agent Orange with three clinical endpoints: age at diagnosis of PCa, age at diagnosis of metastatic PCa, and age at death from PCa. We also analyzed self-reported racial/ethnic subgroups. As very few participants identified as being of both Black race and Hispanic ethnicity, we included these in a single category for Black or African-American race. Where individuals did not meet the endpoint of interest, we censored at age at last follow-up. For Agent Orange analyses, we only included MVP participants who were on active duty during the Vietnam War. We also tested each component of HLS on univariable analysis.

To assess for independent association of HLS and Agent Orange exposure with PCa endpoints when accounting for inherited risk, we used multivariable Cox proportional hazards

models. We have previously shown that combining race/ethnicity, family history and PHS290 provides better risk stratification than any single factor alone.[1] Here, we tested HLS and Agent Orange associations in models with race/ethnicity and family history, without and with PHS290. For race/ethnicity hazard ratios, we used Non-Hispanic White as reference. For PHS290, we illustrated the effect size via the hazard ratio for the highest 20% vs. lowest 20% of genetic risk (HR80/20) and between other strata of PHS290. These percentiles refer to previously defined thresholds of PHS290 derived from European men unaffected by PCa and <70 years old. Further details and assessment of alternate strategies in the MVP population is described elsewhere.[5,21] We assessed statistical significance with two-tailed alpha at 0.01.

Dietary factors: exploratory analysis

We conducted an exploratory analysis using responses to 126 dietary questions (at MVP enrollment), testing for univariable association with the three PCa endpoints. Cox model *p*-values and hazard ratios (with 95% confidence intervals) were tabulated to inform future studies.

Results

Association of HLS with PCa endpoints

HLS was associated with lower risk of metastatic PCa (HR per unit/point of HLS: 0.77, 95% CI 0.73–0.81, *p*<0.001) and of fatal PCa (HR 0.73, 95% CI 0.67–0.81, *p*<0.001) in univariable analysis (**Supplemental Table 1**). HLS had a statistically significant but very small effect on the risk of any PCa (HR 0.98, 95% CI 0.96–0.99, *p*<0.005). Black participants with higher HLS similarly had reduced risk of metastatic (HR 0.83, 95% CI 0.74–0.94, *p*=0.002) and fatal PCa (HR 0.78, 95% CI 0.61–1.01, *p*=0.06), with less impact on any PCa (0.99, 95% 0.94–1.02, *p*=0.25). Analogous patterns were seen in the subgroups of non-Hispanic White and Hispanic White participants, while other racial/ethnic subgroup analyses—with fewer participants—did not show statistically significant associations. The distribution of HLS across racial/ethnic groups is shown in **Supplemental Figure 1**.

On univariable analysis of HLS components (**Supplemental Table 2**), non-smokers were less likely to be diagnosed with PCa (OR 0.89, 95% CI 0.86–0.92, p<0.001) and far less likely to develop metastatic PCa (OR 0.50, 95% CI 0.46–0.55, p<0.001) or fatal PCa (OR 0.33, 95% CI 0.28–0.39, p<0.001). This effect was largely consistent across racial/ethnic subgroups. Vigorous exercise ≥2 days per week was associated with lower risk of PCa diagnosis, (OR 0.95, 95% CI 0.93–0.98, p<0.001) metastatic (OR 0.74, 95% CI 0.68–0.81, p<0.001), and fatal PCa (OR 0.74, 95% CI 0.64–0.86, p<0.001). Conversely, BMI ≤30 was associated with increased risk of fatal PCa (HR 1.22, 95% CI 1.05–1.42, p=0.011) and not associated with diagnosis of any or metastatic PCa. Similar patterns were found when BMI was assessed as a continuous variable (**Supplemental Table 2**).

HLS and inherited PCa risk

When accounting for race/ethnicity and family history in multivariable analysis, HLS was independently associated with reduced metastatic (HR 0.82, 95% CI 0.77–0.87, p<0.001) and fatal PCa (HR 0.76, 95% CI 0.68–0.86, p<0.01) (**Table 2**) but not PCa diagnosis (HR 1.01, 95% CI 0.99–1.03). Cause-specific cumulative incidence curves for metastatic PCa and PCa death diverged for men with high (3) and low (0–1) HLS (**Figure 1**). The absolute reduction in risk was greater among men with high genetic risk (**Supplemental Figure 2**). Notably, healthy lifestyle also mitigated the cumulative incidence of metastatic PCa in Black men (**Figure 2**).

When accounting for genetic risk (PHS290) as well as race/ethnicity and family history, HLS remained independently associated with reduced metastatic (HR 0.82, 95% CI 0.78–0.87, p<10^{-16}) and fatal PCa (HR 0.76, 95% CI 0.68–0.86, p<0.01) (**Table 3**). In this multivariable analysis, HLS was not associated with reduced risk of PCa diagnosis (HR 1.01, 95% CI 1.00–1.03). When accounting for the top 10 principal components of the multivariable analysis, the effect of HLS on reducing the risks of metastatic (HR 0.83, 95% CI 0.78–0.88, p<10^{-16}) and fatal (HR 0.76, 95% CI 0.69–0.85, p<0.01) PCa risks remained significant (**Supplemental Table 3)**.

Agent Orange exposure and PCa risk

Exposure to Agent Orange was associated with increased PCa diagnosis (HR 1.04, 95% CI 1.01–1.06, p=0.003) (**Supplemental Table 4**), primarily among Non-Hispanic White men (HR 1.09, 95% CI 1.06–1.12, p<0.001). When accounting for race/ethnicity and family history, Agent Orange exposure remained an independent risk factor for PCa diagnosis (HR 1.06, 95% CI 1.04–1.09, p<0.05), but not for PCa metastasis (HR 1.08, 95% CI 0.99–1.17) or death (HR 1.02, 95% CI 0.84–1.22) (**Table 4**).

Exploratory environmental exposure analysis

In the exploratory analysis of 126 baseline survey questions, 84, 73 and 41 variables had univariable statistically significant association with PCa diagnosis, metastatic PCa and PCa death, respectively (**Supplemental Table 5**). Highly significant variables associated with increased PCa risks included vitamin D and calcium supplementation; consumption of fried foods; processed meats; sugary drinks/snacks; and daily alcohol use.

Discussion

In a diverse, population-based cohort, healthy lifestyle mitigated inherited risk of PCa—and especially risk of metastatic and fatal PCa. These findings build on those of a previous study that found healthy lifestyle was associated with reduced lethal PCa (combining metastatic and fatal PCa) among White health professionals with high genetic risk.[16] The present work demonstrates healthy lifestyle mitigates inherited risk across the full spectrum of PHS290 and across diverse racial/ethnic groups, including Black men. This is important because Black men are, on average, at high risk of PCa mortality. HLS was independently associated with lower risk of metastatic and fatal PCa even when simultaneously accounting for the strong effects of family history, race/ethnicity, and genetic risk.

We note that relationships between ancestry, family history, and genetic risk are especially complicated in the US due to a variety of factors, including but not limited to high

diversity, structural racism, and social biases. As such, the three measures of inherited PCa risks used in this study are likely interrelated. To mirror current clinical guidelines, and because genetic ancestry is not available clinical encounters, we used self-reported ancestry for the primary analyses. Self-reported race/ethnicity, as a social construct, may also more faithfully reflect the social determinants of health associated with PCa risks and outcomes.[23-26] Previously, we found that using genetic ancestry rather than self-reported ancestry yielded essentially unchanged results.[1,5] Likewise, adjusting for the 10 top principal components of genetic variation did not remove the effect of HLS in the present study. Due to small numbers, we considered Hispanic ethnicity separately within White men but not within other races. Recent work suggests significant differences in PCa risk among US Hispanic men based on country of origin.[7,27] Future work would benefit from the ability to conduct subgroup comparisons among Hispanic/Latino US men. As with race/ethnicity, family history of PCa is also likely measuring a combination of genetic risk, social determinants of health, and even learned behaviors like smoking and exercise habits.

Though the concept of healthy lifestyle mitigating inherited risk was validated in the present work, an optimal healthy lifestyle remains to be determined. The univariable results for the individual components of the score used here show that most of the healthy lifestyle effect was driven by not smoking, followed by frequent exercise. BMI displayed an inverse trend in our analysis, with higher BMI being associated with lower PCa risks. Therefore, the BMI component may have resulted in a slight underestimation of the observed benefits of not smoking and exercise.

Because the MVP questionnaire did not include the same questions used in similar PCa studies[16] and a validated diet score could not be reproduced with the available data, we did not include diet in the HLS. On exploratory analysis, the association of individual diet components with PCa risks were generally consistent with prior studies in other datasets.[8,14,15] Consumption of processed meat products, eggs, fried foods, whole milk and sugary beverages were associated with increased PCa risks. Conversely, consumption of nuts, coffee, chocolate, and tomatoes were associated with lower PCa risks. Supplementation with multi-vitamins and Omega 3 fatty acids were associated with lower risk of PCa metastasis and cause-specific death, while supplementation with Calcium and Vitamin D were associated with increased risks. Notably, this analysis assumed a linearity of the raw data. Future studies should explore how different thresholds of each of these variables impact PCa diagnosis and clinical outcomes.

We found an association between Agent Orange exposure and PCa diagnosis. Previous studies have found a slightly lower age at diagnosis, higher incidence of Stage IV disease and lower rates of biochemical control, but differences in overall survival or other clinical outcomes have not been found.[12,28,29] Similarly, our finding that Agent Orange exposure among MVP participants has a stronger association with PCa diagnosis than with aggressive cancer outcomes may be reassuring when counseling men in this population. However, the present dataset lacks any detail regarding duration or intensity of Agent Orange exposure.

This study was conducted using the MVP dataset and so the results and conclusions may not be generalizable beyond the VA population. As sequencing for rare pathogenic mutations was not performed, it was not possible to assess the impact of a healthy lifestyle on risk arising from, for example, germline *BRCA2* mutations. Potential differences in PCa

screening intensity between exposure groups were also not accounted for.[16] Prior efforts to account for screening intensity in MVP have been mired by confounding effects because of the retrospective nature and unknown reasons for PSA tests ordered.[1] Finally, HLS was only measured at the time of MVP enrollment, and so does not capture fluctuations in behaviors and lifestyle over time. Future work should evaluate how longitudinal lifestyle factors (duration, age of adoption, timing before or after diagnosis, years since quitting smoking etc.) impact a man's PCa risk.

Conclusions

Healthy lifestyle is independently associated with reduced risk of metastatic and fatal PCa and offsets major inherited risk factors (family history, Black race and high genetic risk). Among men who were on active duty during the Vietnam War, Agent Orange exposure is also identified as a risk factor for PCa diagnosis, metastasis and cause-specific mortality. Prospective studies should investigate whether healthy lifestyle interventions can reduce PCa risks, especially in men identified as having high inherited risk.

Pagadala, M. S. *et al.* Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program. *medRxiv*, 2021.2009.2024.21264093 (2022). https://doi.org:10.1101/2021.09.24.21264093

Seibert, T. M. *et al.* Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.

Darst, B. F. *et al.* Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk.

Conti, D. V. *et al.* Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

Huynh-Le, M. A.-O. *et al.* Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. LID - 10.1038/s41391-022-00497-7 [doi].

Huynh-Le, M. A.-O. *et al.* Age dependence of modern clinical risk groups for localized prostate cancer-A population-based study.

Chinea, F. M. *et al.* Ethnic heterogeneity and prostate cancer mortality in Hispanic/Latino men: a population-based study. *Oncotarget* **8**, 69709-69721 (2017). https://doi.org:10.18632/oncotarget.19068

Wilson, K. M. & Mucci, L. A. Diet and Lifestyle in Prostate Cancer.

Rivera-Izquierdo, M. A.-O. *et al.* Obesity and biochemical recurrence in clinically localised prostate cancer: a systematic review and meta-analysis of 86,490 patients. LID - 10.1038/s41391-021-00481-7 [doi].

Zhang, X. *et al.* Impact of obesity upon prostate cancer-associated mortality: A meta-analysis of 17 cohort studies.

Islami, F., Moreira, D. M., Boffetta, P. & Freedland, S. J. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies.

Chang, C., Benson, M. & Fam, M. M. A review of Agent Orange and its associated oncologic risk of genitourinary cancers.

Polychlorinated dibenzo-para-dioxins.

Langlais, C. S. *et al.* Post-Diagnostic Dietary and Lifestyle Factors and Prostate Cancer Recurrence, Progression, and Mortality. *Current oncology reports* **23**, 37-37 (2021). https://doi.org:10.1007/s11912-021-01017-x

Key, T. A.-O. X. *et al.* Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies.

Plym, A. *et al.* A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer. *Eur Urol* (2022). https://doi.org:10.1016/j.eururo.2022.05.008

Khera, A. V. *et al.* Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease.

Arthur, R. S., Wang, T., Xue, X., Kamensky, V. & Rohan, T. E. Genetic Factors, Adherence to Healthy Lifestyle Behavior, and Risk of Invasive Breast Cancer Among Women in the UK Biobank. *JNCI: Journal of the National Cancer Institute* **112**, 893-901 (2020). https://doi.org:10.1093/jnci/djz241

Choi, J., Jia, G., Wen, W., Shu, X. O. & Zheng, W. Healthy lifestyles, genetic modifiers, and colorectal cancer risk: a prospective cohort study in the UK Biobank.

Gaziano, J. M. *et al.* Million Veteran Program: A mega-biobank to study genetic influences on health and disease.

Pagadala, M. *et al.* Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer in the multi-ancestry Million Veteran Program cohort. *Journal of Clinical Oncology* **40**, 155-155 (2022). https://doi.org:10.1200/JCO.2022.40.6_suppl.155

Hunter-Zinck, H. *et al.* Genotyping Array Design and Data Quality Control in the Million Veteran Program.

Rebbeck, T. R. Prostate Cancer Disparities by Race and Ethnicity: From Nucleotide to Neighborhood. LID - 10.1101/cshperspect.a030387 [doi] LID - a030387.
Graham-Steed, T. *et al.* 'Race' and prostate cancer mortality in equal-access healthcare systems.
Coughlin, S. S. A review of social determinants of prostate cancer risk, stage, and survival.
Zavala, V. A. *et al.* Cancer health disparities in racial/ethnic minorities in the United States.
Stern, M. C. *et al.* Variability in Cancer Risk and Outcomes Within US Latinos by National Origin and Genetic Ancestry.
Tward, A. E. & Tward, J. D. The Stage at Presentation and Oncologic Outcomes for Agent Orange Exposed and Non-Exposed United States Veterans Diagnosed With Prostate Cancer.
Everly, L. *et al.* Prostate cancer control and survival in Vietnam veterans exposed to Agent Orange.

	All	Non-Hispanic White	Black or African American	Hispanic White	Asian	Native American	Pacific Islander	Other	Unknown
All participants	590,750 (378,366) 281,923	420,473 (299,266) 229,686	102,203 (47,838) 30,270	27,651 (13,407) 9,382	6,644 (3,876) 2,419	5,835 (3,927) 2,562	3,246 (740) 708	8,226 (8,224) 4,398	16,472 (1,088) 2,498
Any prostate cancer	69,137 (49,400) 38,645	48,339 (37,922) 30,896	15,748 (8,613) 5,777	2,120 (8,613) 1,005	376 (287) 198	504 (378) 258	236 (60) 60	720 (720) 417	1,094 (95) 232
Metastatic prostate cancer	6,413 (4,274) 3,250	4,299 (3,199) 2,494	1,604 (804) 550	213 (126) 96	33 (24) 17	48 (35) 20	18 (5) 3	68 (68) 40	130 (13) 30
Fatal prostate cancer	1,858 (1,314) 1,044	1,354 (1,059) 861	363 (192) 127	59 (30) 27	<10	10 (6) 8	<10	19 (19) 12	44 (2) 7
Agent Orange exposure during Vietnam War era	211,180	172,170	23,923	6,370	1,450	2,279	376	4,100	512
Any prostate cancer	29,667 (29,667) 9433	22,303 (22,303) 7515	5,559 (5,559) 1371	796 (796) 253	170 (170) 32	266 (266) 94	41 (41) 16	479 (479) 134	53 (53) 18
Metastatic prostate cancer	2,445 (2,445) 778	1,766 (1,766) 612	511 (511) 118	75 (75) 21	17 (17) 4	18 (18) 5	<10	47 (47) 13	<10
Fatal prostate cancer	518 (518) 156	387 (387) 124	100 (100) 25	14 (14) 3	<10	<10	<10	13 (13) 2	<10

Table 1: Participant characteristics for self-reported race/ethnicity groups and Agent Orange exposure during the Vietnam War. Numbers in parentheses indicate participants who provided family history information. Numbers in italics indicate participants who provided lifestyle information.

Clinical Endpoint	Self-reported Race/Ethnicity							FH	HLS
	Black or African American	Hispanic White	Asian	Native American	Pacific Islander	Other	Unknown		
Fatal Prostate Cancer	2.46 [1.97-2.96]***	1.1 [0.67-1.61]	0.21 [0.0-0.71]	1.29 [0.27-2.48]	1.44 [0.0-4.74]	1.95 [0.91-3.12]	0.54 [0.0-1.75]	1.98 [1.61-2.4]***	0.76 [0.68-0.86]*
Metastatic Prostate Cancer	2.85 [2.57-3.15]***	1.24 [0.96-1.53]	0.9 [0.45-1.43]	1.13 [0.66-1.7]	0.81 [0.0-2.05]	1.69 [1.18-2.26]*	1.65 [0.69-2.74]	1.72 [1.53-1.94]***	0.82 [0.77-0.87]***
Prostate Cancer	2.34 [2.26-2.42]***	1.07 [1.0-1.15]	0.89 [0.77-1.03]	1.09 [0.96-1.23]	1.08 [0.76-1.43]	1.14 [1.02-1.25]*	0.86 [0.66-1.08]	1.92 [1.86-1.97]***	1.01 [0.99-1.03]

Table 2: Multivariable models combining self-reported Race/Ethnicity, Family History (FH) and Healthy Lifestyle Score (HLS) for three prostate cancer clinical endpoints. Cox proportional hazards results for association with age at death from prostate cancer, at diagnosis of metastatic prostate cancer and age at diagnosis with prostate cancer. *P*-values reported are from multivariable models using self-reported race/ethnicity, family history and HLS. Hazard ratios for race/ethnicity were estimated using Non-Hispanic White as reference. Hazard ratios for family history were for one or more first-degree relatives diagnosed with prostate cancer. This multivariable analysis was limited to the 375,763 participants who provided family history information in baseline survey data. Numbers in brackets are 95% confidence intervals. Significant predictors in the multivariable model are indicated by *(p<0.05), **(p<0.01) and *** (p<0.001).

Clinical Endpoint	Self-reported Race/Ethnicity							FH	PHS290 HR$_{80/20}$	HLS
	Black or African American	Hispanic White	Asian	Native American	Pacific Islander	Other	Unknown			
Fatal Prostate Cancer	1.91 [1.52-2.32]***	1.12 [0.68-1.63]	0.29 [0.0-0.98]	1.21 [0.25-2.35]	1.35 [0.0-4.3]	2.0 [0.95-3.22]	0.59 [0.0-1.93]	1.8 [1.46-2.2]***	4.12 [3.44-4.93]***	0.76 [0.68-0.86]*
Metastatic Prostate Cancer	2.25 [2.03-2.49]***	1.27 [0.97-1.57]	1.22 [0.61-1.92]	1.07 [0.62-1.61]	0.78 [0.0-1.92]	1.7 [1.18-2.28]*	1.74 [0.73-2.84]	1.57 [1.4-1.77]***	4.05 [3.63-4.47]***	0.82 [0.78-0.87]***
Prostate Cancer	1.82 [1.76-1.88]***	1.1 [1.02-1.17]*	1.24 [1.06-1.42]*	1.03 [0.91-1.16]	1.08 [0.77-1.41]	1.14 [1.03-1.26]*	0.9 [0.69-1.13]	1.75 [1.69-1.8]***	4.8 [4.66-4.94]***	1.01 [1.0-1.03]

Table 3: Multivariable models combining self-reported Race/Ethnicity, Family History (FH), Healthy Lifestyle Score (HLS) and PHS290 for three prostate cancer clinical endpoints. Cox proportional hazards results for association with age at death from prostate cancer, at diagnosis of metastatic prostate cancer and age at diagnosis with prostate cancer. For PHS290, effect size was illustrated via the hazard ratio (HR$_{80/20}$) for the highest 20% vs. lowest 20% of genetic risk. Hazard ratios for race/ethnicity were estimated using Non-Hispanic White as the reference. Hazard ratios for family history were for one or more first-degree relatives diagnosed with prostate cancer. This multivariable analysis was limited to the 375,763 participants who provided family history information in baseline survey data. Numbers in brackets are 95% confidence intervals. Significant predictors in the multivariable model are indicated by *($p<0.01$) and *** ($p<10^{-16}$).

Clinical Endpoints	Self-Reported Race/Ethnicity							Family History	Agent Orange
	Black or African American	Hispanic White	Asian	Native American	Pacific Islander	Unknown	Other		
Fatal Prostate Cancer	2.37 [1.87-2.92]***	1.09 [0.58-1.65]	0.27 [0.0-0.84]	0.79 [0.0-1.82]	0.0 [0.0-0.0]	NA	2.06 [1.01-3.28]	1.92 [1.47-2.39]***	1.02 [0.84-1.22]
Metastatic Prostate Cancer	2.51 [2.27-2.75]***	1.23 [0.97-1.55]	1.05 [0.58-1.6]	0.94 [0.51-1.38]	0.57 [0.0-1.52]	NA	1.46 [1.07-1.92]	1.5 [1.33-1.7]***	1.08 [0.99-1.17]
Any Prostate Cancer	2.2 [2.14-2.27]***	1.02 [0.95-1.1]	0.88 [0.75-1.02]	1.02 [0.91-1.15]	0.91 [0.65-1.21]	NA	1.06 [0.96-1.16]	1.86 [1.8-1.92]***	1.06 [1.04-1.09]*

Table 4: Multivariable models combining self-reported Race/Ethnicity, Family History and Agent Orange Exposure for three prostate cancer clinical endpoints. Cox proportional hazards results for association with age at death from prostate cancer, at diagnosis of metastatic prostate cancer and age at diagnosis with prostate cancer. P-values reported are from multivariable models using self-reported race/ethnicity, family history and Agent Orange exposure (yes or no). Hazard ratios for race/ethnicity were estimated using Non-Hispanic White as the reference. Hazard ratios for family history were for one or more first-degree relatives diagnosed with prostate cancer. This multivariable analysis was limited to the 375,763 participants who provided family history information in baseline survey data. Numbers in brackets are 95% confidence intervals. Significant predictors in the multivariable model are indicated by *(p<0.05), **(p<0.01) and *** (p<0.001).

Figure 1. Million Veteran Program (MVP) Cause-specific Cumulative Incidence based on Healthy Lifestyle. Cause-specific cumulative incidence within MVP, stratified by Healthy Lifestyle Score (HLS) 0-1 and 3 for **(A)** all prostate cancer, **(B)** metastatic prostate cancer, and **(C)** fatal cancer.

Figure 2. Million Veteran Program (MVP) Cause-specific Cumulative Incidence based on Healthy Lifestyle for White and Black participants. Cause-specific cumulative incidence within MVP, stratified by Healthy Lifestyle Score (HLS) 0-1 and 3 and also by self-reported race for **(A)** all prostate cancer, **(B)** metastatic prostate cancer, and **(C)** fatal cancer. "White" indicates Non-Hispanic White participants, and "Black" indicates Black and Hispanic Black participants.

Race/Ethnicity	Clinical Endpoint	HLS	P
All (n=281,923)	Fatal Prostate Cancer	0.73 [0.67-0.81]	<0.001*
Non-Hispanic White (n=229,686)		0.76 [0.69-0.85]	<0.001*
Black or African American (n=30,270)		0.78 [0.61-1.01]	0.062
Hispanic White (n=9,382)		0.57 [0.33-1.13]	0.046
Asian (n=2,419)		NA	NA
Native American (2,562)		NA	NA
Pacific Islander (n=708)		NA	NA
Other (n=4,398)		0.49 [0.19-1.43]	0.097
Unknown (n=2,498)		NA	NA
All (n=281,923)	Metastatic Prostate Cancer	0.77 [0.73-0.81]	<0.001*
Non-Hispanic White (n=229,686)		0.8 [0.75-0.85]	<0.001*
Black or African American (n=30,270)		0.83 [0.74-0.94]	0.002*
Hispanic White (n=9,382)		0.75 [0.56-1.0]	0.047*
Asian (n=2,419)		0.68 [0.37-1.64]	0.333
Native American (2,562)		0.65 [0.33-1.32]	0.178
Pacific Islander (n=708)		NA	NA
Other (n=4,398)		0.76 [0.49-1.27]	0.276
Unknown (n=2,498)		0.69 [0.42-1.21]	0.184
All (n=281,923)	Any Prostate Cancer	0.98 [0.96-0.99]	0.005*
Non-Hispanic White (n=229,686)		1.01 [0.99-1.03]	0.223
Black or African American (n=30,270)		0.98 [0.94-1.02]	0.246
Hispanic White (n=9,382)		1.05 [0.95-1.15]	0.319
Asian (n=2,419)		1.07 [0.84-1.4]	0.596
Native American (2,562)		1.22 [1.04-1.45]	0.035
Pacific Islander (n=708)		1.19 [0.84-1.65]	0.342
Other (n=4,398)		0.98 [0.84-1.15]	0.846
Unknown (n=2,498)		0.76 [0.63-0.9]	0.004*

Supplemental Table 1: Univariable association of Healthy Lifestyle Score (HLS) with any, metastatic and fatal prostate cancer, stratified by racial/ethnic group. Cox proportional hazards model results from HLS association with age at prostate cancer, metastatic prostate cancer (nodal or distant) and death from prostate cancer. *P*-values reported are from univariable models using HLS as the sole predictor variable. Significant predictors are indicated by *. "NA" indicates groups for which sub analyses were limited by sample size. n, indicates number at risk.

Self-reported Race/Ethnicity	Clinical Endpoint	Smoking Status		Exercise		BMI Binary		BMI Continuous	
		HR	p	HR	p	HR	p	HR	p
All (n=281,923)	Fatal Prostate Cancer	0.33 [0.28-0.39]	<0.001*	0.74 [0.64-0.86]	<0.001*	1.22 [1.05-1.42]	0.011*	0.96 [0.95-0.98]	<0.001*
Non-Hispanic White (n=229,686)		0.35 [0.29-0.42]	<0.001*	0.79 [0.66-0.95]	0.018	1.18 [0.99-1.41]	0.056	0.97 [0.95-0.99]	<0.001*
Black or African American (n=30,270)		0.31 [0.21-0.48]	<0.001*	0.87 [0.6-1.34]	0.488	1.71 [1.14-2.9]	0.019	0.94 [0.9-0.97]	<0.001*
Hispanic White (n=9,382)		0.38 [0.15-1.8]	0.078	0.44 [0.2-1.23]	0.04*	1.01 [0.45-3.14]	0.987	1.01 [0.9-1.09]	0.748
Asian (n=2,419)		NA	NA	NA	NA	NA	NA	NA	NA
Native American (2,562)		NA	NA	NA	NA	NA	NA	NA	NA
Pacific Islander (n=708)		NA	NA	NA	NA	NA	NA	NA	NA
Other (n=4,398)		0.37 [0.1-715491.18]	0.134	0.32 [0.11-	0.085	1.03 [0.23-6.8]	0.968	1.01 [0.86-1.11]	0.925
Unknown (n=2,498)		NA	NA	NA	NA	NA	NA	NA	NA
All (n=281,923)	Metastatic Prostate Cancer	0.5 [0.46-0.55]	<0.001*	0.74 [0.68-0.81]	<0.001*	1.01 [0.94-1.1]	0.751	0.99 [0.99-1.0]	0.132
Non-Hispanic White (n=229,686)		0.52 [0.46-0.58]	<0.001*	0.82 [0.74-0.91]	<0.001*	0.98 [0.9-1.07]	0.700	1.0 [0.99-1.01]	0.515
Black or African American (n=30,270)		0.62 [0.51-0.77]	<0.001*	0.75 [0.63-0.91]	0.003	1.16 [0.98-1.42]	0.116	0.99 [0.97-1.0]	0.102
Hispanic White (n=9,382)		0.56 [0.33-1.19]	0.059	0.6 [0.39-0.98]	0.022	1.06 [0.7-1.67]	0.799	1.0 [0.96-1.04]	0.852
Asian (n=2,419)		NA	NA	NA	NA	NA	NA	NA	NA
Native American (2,562)		0.42 [0.16-2.28]	0.093	0.83 [0.31-4.01]	0.733	0.84 [0.35-2.51]	0.711	1.03 [0.92-1.12]	0.39
Pacific Islander (n=708)		NA	NA	NA	NA	NA	NA	NA	NA
Other (n=4,398)		0.26 [0.14-0.57]	<0.001*	1.32 [0.54-	0.644	1.5 [0.77-3.48]	0.259	0.96 [0.89-1.02]	0.205
Unknown (n=2,498)		0.54 [0.23-2.69]	0.258	0.78 [0.22-1.65]	0.585	0.74 [0.34-1.8]	0.450	1.0 [0.92-1.07]	0.974
All (n=281,923)	Any Prostate Cancer	0.89 [0.86-0.92]	<0.001*	0.95 [0.93-0.98]	<0.001*	1.04 [1.02-1.06]	<0.001*	1.0 [1.0-1.0]	0.052
Non-Hispanic White (n=229,686)		0.93 [0.9-0.97]	<0.001*	0.99 [0.96-1.02]	0.412	1.06 [1.03-1.08]	<0.001*	1.0 [1.0-1.0]	0.296
Black or African American (n=30,270)		0.98 [0.92-1.05]	0.601	1.01 [0.96-1.08]	0.676	0.96 [0.91-1.01]	0.098	1.01 [1.0-1.01]	0.007
Hispanic White (n=9,382)		0.94 [0.76-1.17]	0.563	1.06 [0.91-1.27]	0.446	1.08 [0.94-1.22]	0.270	1.0 [0.99-1.01]	0.725
Asian (n=2,419)		1.78 [0.89-6.02]	0.166	1.09 [0.76-1.68]	0.649	0.91 [0.64-1.37]	0.631	1.03 [1.0-1.06]	0.089
Native American (2,562)		0.95 [0.69-1.34]	0.742	1.34 [0.98-2.08]	0.107	1.28 [1.02-1.63]	0.055	0.99 [0.96-1.01]	0.198
Pacific Islander (n=708)		0.65 [0.34-1.5]	0.241	1.31 [0.79-2.24]	0.307	1.37 [0.83-2.55]	0.260	0.98 [0.93-1.03]	0.333
Other (n=4,398)		0.89 [0.69-1.18]	0.385	0.96 [0.71-1.37]	0.787	1.05 [0.86-1.29]	0.610	1.0 [0.99-1.02]	0.709
Unknown (n=2,498)		0.88 [0.61-1.38]	0.560	0.82 [0.57-1.12]	0.222	0.69 [0.52-0.9]	0.005*	1.03 [1.01-1.05]	0.004*

Supplemental Table 2: Univariable association of each component of healthy lifestyle score with any, metastatic and fatal prostate cancer, stratified by racial/ethnic group. Cox proportional hazards model results from association with age at prostate cancer, metastatic prostate cancer (nodal or distant) and death from prostate cancer. *P*-values reported are from univariable models using each component of the healthy lifestyle score, respectively, as the sole predictor variable. The hazards ratio (HR) for smoking status is for non-smokers, (reference is smokers). The HR for exercise is for those participating in vigorous activity 2 or more days per week (reference is exercise fewer than 2 days per week). The HR for binary BMI is for participants with BMI≤30 kg/m^2 (reference is BMI>30). BMI was also assessed as a continuous variable (HR is per kg/m^2).

Significant predictors are indicated by *. NA, indicates subgroup analyses limited by sample size. n, indicates number at risk.

Clinical Endpoint	Self-reported Race/Ethnicity							FH	PHS290 HR$_{80/20}$	HLS
	Black or African American	Non-Hispanic White	Asian	Native American	Pacific Islander	Other	Unknown			
Fatal Prostate Cancer	0.9 [0.46-1.83]	0.97 [0.51-1.69]	0.17 [0.0-0.95]	1.02 [0.24-1.99]	0.42 [0.0-2.36]	1.67 [0.73-3.06]	0.52 [0.0-1.85]	1.81 [1.47-2.2]***	4.01 [3.33-4.75]***	0.76 [0.69-0.85]*
Metastatic Prostate Cancer	0.81 [0.55-1.21]	1.04 [0.77-1.42]	0.72 [0.2-2.31]	0.83 [0.45-1.27]	0.48 [0.0-1.7]	1.27 [0.85-1.72]	1.45 [0.57-2.5]	1.58 [1.39-1.74]***	3.95 [3.57-4.43]***	0.83 [0.78-0.88]***
Prostate Cancer	1.15 [1.02-1.32]	1.08 [0.98-1.18]	1.13 [0.77-1.57]	1.01 [0.88-1.15]	0.92 [0.59-1.34]	1.06 [0.96-1.19]	0.88 [0.66-1.11]	1.75 [1.7-1.81]***	4.78 [4.64-4.93]***	1.01 [1.0-1.03]
Clinical Endpoint	Principal Components									
	PC1	PC2	PC3	PC4	PC5	PC6	PC7	PC8	PC9	PC10
Fatal Prostate Cancer	0.01 [0.0-0.81]***	0.94 [0.04-11.27]	1.07 [0.01-174.59]	0.05 [0.01-0.28]*	0.09 [0.0-2.08]	4.12 [0.06-199.67]	178.09 [0.11-	0.0 [0.0-1.67]	33.39 [0.09-47477.87]	9.99 [0.08-1119.07]
Metastatic Prostate Cancer	0.0 [0.0-0.03]***	1.15 [0.18-6.94]	1.08 [0.06-20.44]	0.04 [0.01-0.12]***	1.12 [0.18-5.34]	7.63 [0.8-90.05]	0.37 [0.01-40.75]	0.4 [0.01-18.58]	2.64 [0.06-102.86]	0.08 [0.01-1.14]
Prostate Cancer	0.08 [0.04-0.16]***	0.58 [0.36-0.99]	0.8 [0.36-1.73]	0.67 [0.49-0.89]	2.46 [1.43-4.33]*	2.75 [1.44-5.37]*	1.83 [0.53-6.87]	0.38 [0.14-1.06]	0.82 [0.29-2.59]	0.6 [0.27-1.39]

Supplemental Table 3: Principal component analysis of multivariable models combining self-reported Race/Ethnicity, Family History (FH), Healthy Lifestyle Score (HLS) and PHS290 for three prostate cancer clinical endpoints. Cox proportional hazards results for association with age at death from prostate cancer, at diagnosis of metastatic prostate cancer, and age at diagnosis with prostate cancer. Hazard ratios and 95% confidence intervals are from multivariable models using self-reported race/ethnicity, family history, HLS and PHS290. For PHS290, effect size was illustrated via the hazard ratio (HR$_{80/20}$) for the highest 20% vs. lowest 20% of genetic risk. Hazard ratios for race/ethnicity were estimated using Non-Hispanic White as the reference. Hazard ratios for family history were for one or more first-degree relatives diagnosed with prostate cancer. The principal component (PC) analysis was run on standardized variables, and HRs for each PC are reported per unit of PC. Numbers in brackets are 95% confidence intervals. Significant predictors in the multivariable model are indicated by *(p<0.01) and *** (p<10^{-16}).

Race/Ethnicity	Clinical Endpoint	Agent Orange	P
All (n=211,180)		1.01 [0.82-1.22]	0.945
Non-Hispanic White (n=172,170)		1.1 [0.88-1.34]	0.401
Black or African American (n=23,923)		0.9 [0.57-1.38]	0.654
Hispanic White (n=6,370)		0.6 [0.0-1.99]	0.438
Asian (n=1,450)	**Fatal Prostate Cancer**	NA	NA
Native American (n=2,279)		NA	NA
Pacific Islander (n=376)		NA	NA
Other (n=4,100)		0.4 [0.0-1.35]	0.237
Unknown (n=512)		NA	NA
All (n=211,180)		1.05 [0.97-1.15]	0.232
Non-Hispanic White (n=172,170)		1.17 [1.06-1.3]	0.002
Black or African American (n=23,923)		0.86 [0.69-1.04]	0.142
Hispanic White (n=6,370)		0.84 [0.49-1.32]	0.488
Asian (n=1,450)	**Metastatic Prostate Cancer**	0.92 [0.17-2.42]	0.891
Native American (n=2,279)		0.89 [0.2-2.37]	0.831
Pacific Islander (n=376)		NA	NA
Other (n=4,100)		0.88 [0.43-1.63]	0.689
Unknown (n=512)		NA	NA
All (n=211,180)		1.04 [1.01-1.06]	0.003*
Non-Hispanic White (n=172,170)		1.09 [1.06-1.12]	<0.001*
Black or African American (n=23,923)		1.01 [0.95-1.07]	0.858
Hispanic White (n=6,370)		0.99 [0.85-1.15]	0.937
Asian (n=1,450)	**Any Prostate Cancer**	0.68 [0.47-0.97]	0.054
Native American (n=2,279)		1.31 [1.02-1.65]	0.038*
Pacific Islander (n=376)		1.25 [0.66-2.35]	0.494
Other (n=4,100)		0.91 [0.75-1.1]	0.330
Unknown (n=512)		0.85 [0.44-1.49]	0.586

Supplemental Table 4: Univariable association of Agent Orange with any, metastatic and fatal prostate cancer. Hazard ratios from Cox Proportional Hazards model of Agent Orange exposure with age at prostate cancer, metastatic prostate cancer (nodal or distant) and death from prostate cancer. *P*-values reported are from univariable models using Agent Orange exposure (yes or no) as the sole predictor variable. Significant predictors in the multivariable model are indicated by *. NA, indicates groups for which sub analyses were limited by sample size. n, indicates number at risk.

Variable	Description	Any Prostate Cancer		Metastatic Prostate Cancer		Fatal Prostate Cancer	
		OR	p-value	OR	p-value	OR	p-value
alcfreq	How often a drink that contains alcohol?	1.01 [1.01-1.02]	3.14E-07	0.97 [0.95-0.99]	4.70E-04	0.96 [0.93-1.0]	6.24E-03
alcqty	How many drinks containing alcohol on a typical day when you are drinking?	1.08 [1.06-1.11]	2.64E-25	1.35 [1.26-1.43]	1.61E-33	1.36 [1.18-1.53]	1.20E-09
bakebutter	Subject uses real butter for baking at home	1.02 [1.0-1.04]	1.18E-02	1.04 [0.97-1.12]	2.43E-01	0.94 [0.82-1.06]	3.45E-01
bakelard	Subject uses lard for baking at home	0.95 [0.87-1.04]	1.31E-01	1.05 [0.72-1.38]	7.62E-01	0.91 [0.44-1.43]	7.46E-01
bakemarg	Subject uses margarine for baking at home	1.03 [1.0-1.05]	2.88E-03	0.93 [0.85-1.01]	9.02E-02	0.99 [0.84-1.15]	8.78E-01
bakevegoil	Subject uses vegetable oil for baking at home	1.0 [0.98-1.02]	8.22E-01	1.05 [0.98-1.13]	1.65E-01	1.11 [0.97-1.25]	9.65E-02
bakevegshort	Subject uses vegetable shortening for baking at home	0.98 [0.95-1.01]	6.11E-02	0.88 [0.78-0.99]	4.38E-02	0.89 [0.71-1.07]	2.67E-01
circcad	Have you been diagnosed with Coronary Artery / Coronary Heart Disease (including heart attack, angina)	0.78 [0.76-0.81]	1.50E-131	0.65 [0.59-0.72]	2.72E-32	0.75 [0.63-0.88]	1.25E-06
circcadmed	Do you take medication for Coronary Artery / Coronary Heart Disease	0.79 [0.76-0.81]	1.40E-111	0.65 [0.59-0.73]	9.49E-28	0.74 [0.62-0.87]	3.61E-06
circchf	Have you been diagnosed with Congestive Heart Failure	0.78 [0.75-0.81]	7.71E-55	0.64 [0.54-0.74]	6.03E-14	0.64 [0.49-0.82]	1.58E-05
circchfmed	Do you take medication for High blood pressure / hypertension	0.79 [0.75-0.83]	5.57E-43	0.68 [0.57-0.79]	6.84E-10	0.64 [0.47-0.85]	5.55E-05
circchol	Have you been diagnosed with High Cholesterol	1.03 [1.0-1.05]	1.22E-03	0.88 [0.82-0.94]	5.63E-07	0.96 [0.84-1.09]	4.05E-01
circcholmed	Do you take medication for High Cholesterol	1.01 [0.99-1.03]	3.27E-01	0.86 [0.8-0.92]	8.67E-09	0.91 [0.8-1.03]	4.90E-02
circhrtatk	Have you been diagnosed with Heart Attack	0.81 [0.79-0.84]	9.48E-74	0.72 [0.64-0.8]	1.88E-16	0.92 [0.77-1.07]	1.82E-01
circhrtatkmed	Do you take medication for Heart Attack	0.81 [0.78-0.83]	1.10E-69	0.76 [0.67-0.84]	4.46E-11	0.82 [0.67-0.98]	4.13E-03
circhtn	Have you been diagnosed with High blood pressure / hypertension	1.02 [1.0-1.04]	3.29E-03	0.97 [0.9-1.04]	2.94E-01	0.99 [0.88-1.14]	8.86E-01
circhtnmed	Do you take medication for High blood pressure / hypertension	1.01 [0.98-1.03]	3.19E-01	0.94 [0.87-1.01]	1.51E-02	0.95 [0.84-1.09]	2.63E-01
circpvd	Have you been diagnosed with Peripheral Vascular Disease	0.84 [0.8-0.88]	1.81E-23	0.76 [0.63-0.88]	1.48E-05	0.87 [0.66-1.14]	1.74E-01
circpvdmed	Do you take medication for Peripheral Vascular Disease	0.83 [0.78-0.87]	4.36E-20	0.79 [0.63-0.94]	1.13E-03	0.99 [0.69-1.32]	9.48E-01
circstrk	Have you been diagnosed with Stroke	0.94 [0.9-0.98]	4.19E-05	0.84 [0.71-0.96]	7.49E-04	0.9 [0.69-1.13]	2.23E-01
circstrkmed	Do you take medication for Stroke	0.92 [0.88-0.97]	4.03E-06	0.9 [0.76-1.05]	8.27E-02	1.03 [0.76-1.31]	7.82E-01
circtia	Have you been diagnosed with Transient Ischemic Attack (TIA)	0.92 [0.88-0.97]	5.64E-06	0.58 [0.47-0.69]	2.26E-14	0.69 [0.49-0.9]	6.84E-04
circtiamed	Do you take medication for Transient Ischemic Attack (TIA)	0.93 [0.87-0.98]	2.45E-04	0.71 [0.56-0.86]	2.02E-05	0.88 [0.62-1.19]	3.14E-01
dodm	Have you been diagnosed with Diabetes/Sugar	0.87 [0.85-0.89]	1.44E-57	0.91 [0.84-0.99]	2.06E-03	1.05 [0.91-1.2]	3.72E-01
dodmmed	Do you take medication for Diabetes/ Sugar	0.85 [0.83-0.87]	3.04E-70	0.9 [0.83-0.98]	1.43E-03	1.03 [0.89-1.19]	5.53E-01
ffqbacon	Subject's average consumption of bacon (2 slices), in the last year	1.02 [1.01-1.03]	9.61E-10	1.04 [1.02-1.07]	2.00E-05	1.04 [0.99-1.09]	2.62E-02
ffqbeef	Subject's average consumption of Beef, pork, or lamb as a sandwich or mixed dish, in the last year	1.0 [0.99-1.01]	9.06E-01	1.02 [0.99-1.05]	1.25E-01	1.06 [1.0-1.12]	3.81E-03
ffqbeef_2	Subject's average consumption of beef, pork, or lamb as a main dish (4-6 oz) in the last year	1.0 [0.99-1.01]	5.06E-01	1.0 [0.97-1.03]	9.67E-01	1.03 [0.97-1.09]	1.84E-01
ffqbeer	Subject's average consumption of beer (1 glass, bottle, can) in the last year	1.02 [1.01-1.02]	7.28E-17	1.0 [0.97-1.02]	7.01E-01	0.94 [0.9-0.98]	2.72E-04
ffqcake	Subject's average consumption of cake (slice) in the last year	0.99 [0.98-1.0]	8.73E-02	0.93 [0.89-0.96]	3.29E-07	0.97 [0.91-1.04]	2.83E-01
ffqcandy	Subject's average consumption of candy without chocolate (1 oz.) in the last year	1.0 [0.99-1.0]	9.65E-02	0.97 [0.94-0.99]	4.76E-04	0.99 [0.94-1.03]	4.30E-01
ffqcarbbev	Subject's average consumption of carbonated beverages with sugar in the last year	1.03 [1.02-1.03]	4.19E-26	1.03 [1.01-1.06]	3.60E-05	1.05 [1.0-1.09]	3.31E-03
ffqchips	Subject's average consumption of potato chips or corn chips (small bag or 1 oz.) in the last year	1.01 [1.0-1.01]	3.58E-02	1.0 [0.97-1.02]	7.18E-01	0.98 [0.94-1.03]	3.80E-01
ffqchknoskn	Subject's average consumption of chicken or turkey, without skin (4 - 6 oz), in the last year	1.01 [1.0-1.02]	6.22E-02	0.99 [0.96-1.02]	2.32E-01	1.02 [0.96-1.08]	3.80E-01

ffqchoc	Subject's average consumption of chocolate (1 oz.) in the last year	0.98 [0.97-0.99]	2.09E-19	0.93 [0.91-0.96]	3.90E-15	0.96 [0.92-0.99]	2.25E-03
ffqcknskn	Subject's average consumption of chicken or turkey, with skin (4 - 6 oz), in the last year	1.04 [1.03-1.05]	1.10E-44	1.08 [1.06-1.11]	1.17E-16	1.05 [1.0-1.1]	3.22E-03
ffqcldcer	Subject's average consumption of cold breakfast cereal (1 cup) in the last year	0.98 [0.98-0.99]	4.25E-13	0.93 [0.91-0.95]	9.40E-22	0.98 [0.95-1.02]	2.09E-01
ffqcof	Subject's average consumption of caffeinated coffee (1 cup) in the last year	0.98 [0.98-0.98]	1.26E-47	0.99 [0.98-1.0]	2.91E-02	0.96 [0.94-0.98]	5.15E-06
ffqcookie	Subject's average consumption of cookies (1) in the last year	0.98 [0.97-0.98]	2.52E-22	0.9 [0.88-0.92]	6.70E-32	0.92 [0.88-0.96]	3.52E-08
ffqdbttr	Subject's average consumption of butter (pat), added to food or bread, in the last year	1.0 [0.99-1.0]	6.46E-02	1.0 [0.99-1.02]	4.89E-01	1.0 [0.97-1.03]	7.57E-01
ffqdcottage	Subject's average consumption of cottage or ricotta cheese (1/2 cup) in the last year	0.97 [0.96-0.98]	7.76E-22	0.99 [0.96-1.02]	2.76E-01	1.02 [0.96-1.08]	2.42E-01
ffqdicecrm	Subject's average consumption of ice cream (1 cup) in the last year	0.97 [0.96-0.98]	8.39E-25	0.93 [0.91-0.96]	3.88E-13	1.02 [0.98-1.07]	2.19E-01
ffqdmarg	Subject's average consumption of margarine (pat), added to food or bread, in the last year	0.99 [0.99-1.0]	1.75E-03	0.99 [0.97-1.01]	8.16E-02	1.01 [0.98-1.04]	2.71E-01
ffqdothchs	Subject's average consumption of other cheese (1 slice or 1 oz. serving) in the last year	0.98 [0.97-0.99]	5.19E-14	0.96 [0.94-0.99]	2.74E-05	0.98 [0.94-1.03]	2.50E-01
ffqdressing	Subject's average consumption of other oil and vinegar dressing, e.g., Italian (1 Tbs) in the last year	1.0 [0.99-1.01]	9.12E-01	0.96 [0.93-0.98]	6.94E-07	0.96 [0.92-1.0]	1.79E-02
ffqdrkbrd	Subject's average consumption of dark bread, including wheat pita bread (slice), in the last year	1.0 [0.99-1.0]	6.36E-02	0.99 [0.97-1.01]	9.21E-02	0.98 [0.95-1.02]	1.95E-01
ffqdskim	Subject's average consumption of skim or low fat milk (8 oz. glass) in the last year	0.99 [0.98-0.99]	2.24E-11	0.95 [0.93-0.97]	2.06E-18	0.99 [0.96-1.01]	1.47E-01
ffqdtcarbbev	Subject's average consumption of low calorie carbonated beverages in the last year	0.97 [0.97-0.98]	2.74E-36	0.94 [0.92-0.97]	7.39E-14	0.98 [0.95-1.02]	2.33E-01
ffqdwhl	Subject's average consumption of whole milk (8 oz. glass) in the last year	1.0 [1.0-1.01]	2.29E-01	1.04 [1.01-1.06]	5.04E-06	1.04 [1.0-1.08]	4.34E-03
ffqdyog	Subject's average consumption of yogurt (1 cup) in the last year	1.01 [1.0-1.01]	1.93E-02	0.98 [0.96-1.0]	1.67E-02	1.01 [0.97-1.05]	5.11E-01
ffqegg	Subject's average consumption of eggs (1) in the last year	0.99 [0.99-1.0]	4.87E-03	1.02 [1.0-1.05]	1.56E-02	1.07 [1.03-1.12]	1.42E-05
ffqfappl	Subject's average consumption of fresh apples or pears, in the last year	1.0 [0.99-1.01]	8.77E-01	0.99 [0.96-1.01]	1.07E-01	1.0 [0.96-1.05]	8.95E-01
ffqfat	Amount of visible fat on beef/pork/lamb that subject removes before eating	1.02 [1.01-1.03]	6.59E-06	1.08 [1.04-1.11]	1.15E-10	0.99 [0.94-1.06]	7.39E-01
ffqfbanan	Subject's average consumption of bananas in the last year	0.99 [0.99-1.0]	8.96E-04	0.96 [0.94-0.98]	7.33E-08	0.98 [0.95-1.02]	2.47E-01
ffqfish	Subject's average consumption of fish (3-5 oz.) in the last year	1.03 [1.02-1.04]	1.32E-16	1.01 [0.98-1.05]	3.42E-01	0.95 [0.89-1.0]	1.27E-02
ffqfojgfj	Subject's average consumption of orange juice or grapefruit juice (small glass), in the last year	1.0 [0.99-1.0]	7.61E-02	0.97 [0.95-0.99]	1.86E-05	0.96 [0.93-0.99]	6.23E-04
ffqforng	Subject's average consumption of oranges, in the last year	1.0 [1.0-1.01]	1.53E-01	1.01 [0.98-1.03]	3.55E-01	1.01 [0.97-1.06]	6.52E-01
ffqfoth	Subject's average consumption of other fruits (fresh, frozen, or canned) in the last year	0.99 [0.99-1.0]	3.51E-03	0.98 [0.95-1.0]	4.62E-03	1.02 [0.99-1.06]	1.20E-01
ffqfpeach	Subject's average consumption of peaches, apricots, or plums (1 fresh, or 1/2 cup canned), in the last year	0.99 [0.98-1.0]	9.42E-06	0.97 [0.95-1.0]	1.01E-02	1.01 [0.97-1.06]	3.93E-01
ffqfrudrnk	Subject's average consumption of Hawaiian Punch, lemonade, or other fruit drinks in the last year	1.03 [1.02-1.04]	3.64E-33	1.07 [1.05-1.09]	7.23E-16	1.06 [1.02-1.11]	3.56E-05
ffqfryaway	Subject's consumption of fried foods away from home	1.02 [1.0-1.04]	2.41E-03	1.01 [0.95-1.08]	5.57E-01	1.04 [0.92-1.17]	3.41E-01
ffqfryhome	Subject's consumption of fried foods at home	0.98 [0.97-1.0]	1.32E-03	1.06 [1.01-1.11]	1.43E-03	1.08 [0.97-1.18]	2.29E-02
ffqhambrg	Subject's average consumption of hamburger (1 patty), in the last year	0.97 [0.96-0.98]	1.59E-13	0.97 [0.94-1.01]	3.41E-02	1.06 [0.99-1.13]	7.74E-03
ffqhtdog	Subject's average consumption of hot dogs (1), in the last year	1.0 [0.99-1.01]	9.07E-01	1.03 [0.99-1.07]	2.76E-02	1.08 [1.01-1.15]	8.47E-04
ffqliquor	Subject's average consumption of liquor (1 drink or shot) in the last year	1.01 [1.01-1.02]	7.02E-10	1.0 [0.97-1.02]	6.74E-01	0.99 [0.95-1.03]	6.46E-01
ffqliver	Subject's average consumption of liver (3-4 oz), in the last year	1.05 [1.03-1.07]	1.07E-14	1.15 [1.09-1.22]	4.63E-11	1.08 [0.96-1.2]	7.36E-02
ffqnuts	Subject's average consumption of nuts (small packet or 1 oz.) in the last year	1.0 [0.99-1.0]	2.38E-01	0.96 [0.93-0.98]	1.17E-07	0.94 [0.9-0.98]	5.05E-05
ffqpb	Subject's average consumption of peanut butter (1 Tbs) in the last year	0.97 [0.97-0.98]	2.21E-28	0.97 [0.95-1.0]	7.41E-04	0.99 [0.95-1.03]	4.27E-01

ffqpiehm	Subject's average consumption of homemade pie (slice) in the last year	1.0 [0.99-1.01]	4.89E-01	0.97 [0.93-1.01]	3.91E-02	1.01 [0.94-1.09]	6.88E-01
ffqpierm	Subject's average consumption of ready made pie (slice) in the last year	0.99 [0.98-1.01]	1.86E-01	0.96 [0.92-1.0]	7.56E-03	0.99 [0.92-1.06]	7.77E-01
ffqpotbkd	Subject's average consumption of baked, boiled (1) or mashed (1 cup) potatoes in the last year	0.98 [0.97-0.99]	2.93E-10	0.97 [0.93-1.0]	1.74E-03	1.0 [0.95-1.06]	8.41E-01
ffqpotfried	Subject's average consumption of French fried potatoes (4 oz.) in the last year	1.02 [1.01-1.03]	1.08E-06	1.03 [1.0-1.07]	6.02E-03	1.04 [0.98-1.11]	4.95E-02
ffqprocmeat	Subject's average consumption of processed meats e.g., sausage, salami, bologna, etc (piece or slice), in the last year	0.99 [0.98-1.0]	8.27E-04	0.97 [0.95-1.0]	1.06E-02	1.01 [0.96-1.06]	5.50E-01
ffqrice	Subject's average consumption of rice or pasta, e.g., spaghetti, noodles, etc. (1 cup) in the last year	1.01 [1.0-1.02]	1.13E-04	1.03 [1.0-1.07]	4.49E-03	1.07 [1.01-1.13]	8.02E-04
ffqrxdiet	Subject follows a physician-prescribed special diet	0.97 [0.95-1.0]	2.31E-03	0.93 [0.85-1.01]	1.69E-02	1.03 [0.89-1.2]	5.51E-01
ffqrxdietchol	Subject follows a low cholesterol diet	1.0 [0.97-1.04]	6.90E-01	0.97 [0.86-1.07]	4.32E-01	0.99 [0.8-1.2]	8.67E-01
ffqrxdietdiab	Subject follows a diabetic diet	0.92 [0.89-0.95]	1.10E-13	0.89 [0.79-1.0]	6.80E-03	0.98 [0.79-1.2]	7.46E-01
ffqrxdietfat	Subject follows a low-fat diet	0.94 [0.9-0.98]	2.42E-05	0.87 [0.75-0.99]	6.13E-03	0.96 [0.76-1.21]	6.70E-01
ffqrxdietoth	Subject follows another physician-prescribed diet	1.03 [0.96-1.09]	2.17E-01	0.89 [0.69-1.11]	1.66E-01	1.19 [0.8-1.65]	1.68E-01
ffqrxdietpot	Subject follows a high potassium diet	1.02 [0.93-1.11]	5.60E-01	1.03 [0.75-1.33]	7.61E-01	1.2 [0.74-1.8]	2.63E-01
ffqrxdietsod	Subject follows a low sodium diet	0.97 [0.93-1.0]	4.77E-03	0.88 [0.78-0.99]	4.47E-03	0.92 [0.74-1.12]	2.57E-01
ffqrxdiettrig	Subject follows a low triglyceride diet	0.92 [0.88-0.98]	2.06E-04	0.79 [0.61-0.97]	2.63E-03	0.79 [0.51-1.11]	1.04E-01
ffqrxdietulc	Subject follows an ulcer diet	1.03 [0.9-1.19]	4.93E-01	0.82 [0.45-1.25]	2.74E-01	1.41 [0.59-2.36]	1.46E-01
ffqrxdietwtred	Subject follows a weight reduction (low calorie) diet	1.06 [1.02-1.11]	8.22E-05	1.0 [0.85-1.15]	9.57E-01	1.02 [0.73-1.31]	8.66E-01
ffqsugar	Teaspoons of sugar that subject adds to beverages or food daily	1.0 [1.0-1.0]	4.84E-08	1.0 [1.0-1.0]	2.39E-03	1.0 [0.99-1.01]	1.77E-04
ffqvbean	Subject's average consumption of baked or dried beans or lentils (1/2 cup) in the last year	0.99 [0.99-1.0]	7.29E-02	1.01 [0.98-1.04]	2.36E-01	1.0 [0.95-1.06]	9.32E-01
ffqvbroc	Subject's average consumption of broccoli (1/2 cup) in the last year	1.03 [1.02-1.03]	3.62E-16	1.05 [1.02-1.08]	8.38E-06	1.03 [0.97-1.09]	1.34E-01
ffqvcarcook	Subject's average consumption of cooked carrots (1/2 carrot or 2-4 sticks) in the last year	0.99 [0.98-1.0]	3.56E-04	1.01 [0.98-1.04]	2.85E-01	1.02 [0.96-1.08]	3.72E-01
ffqvcarraw	Subject's average consumption of raw carrots (1/2 carrot or 2-4 sticks) in the last year	1.0 [1.0-1.01]	1.11E-01	1.0 [0.97-1.03]	9.16E-01	0.96 [0.92-1.02]	3.66E-02
ffqvcbg	Subject's average consumption of cabbage, cauliflower or Brussels sprouts (1/2 cup) in the last year	1.01 [1.0-1.02]	4.83E-02	1.05 [1.02-1.08]	3.17E-06	1.06 [1.0-1.12]	3.16E-03
ffqvcorn	Subject's average consumption of corn (1 ear or 1/2 cup frozen or canned) in the last year	1.0 [0.99-1.01]	4.18E-01	1.0 [0.97-1.04]	7.40E-01	1.0 [0.95-1.06]	9.08E-01
ffqvpea	Subject's average consumption of peas or lima beans (1/2 cup fresh, frozen canned) in the last year	1.0 [0.99-1.01]	5.62E-01	1.0 [0.97-1.04]	6.92E-01	1.0 [0.94-1.06]	8.33E-01
ffqvspin	Subject's average consumption of cooked spinach or collard greens (1/2cup) in the last year	1.04 [1.04-1.05]	2.80E-44	1.08 [1.05-1.12]	2.27E-14	1.05 [1.0-1.11]	1.07E-02
ffqvsqsh	Subject's average consumption of yellow (winter) squash (1/2 cup) in the last year	1.0 [0.99-1.01]	4.94E-01	0.98 [0.95-1.02]	2.76E-01	1.02 [0.95-1.1]	3.74E-01
ffqvstngbns	Subject's average consumption of string beans (1/2 cup) in the last year	1.01 [1.0-1.02]	5.04E-02	0.99 [0.96-1.02]	5.17E-01	0.99 [0.93-1.04]	6.00E-01
ffqvtom	Subject's average consumption of tomatoes (1) or tomato juice (small glass) in the last year	0.98 [0.97-0.98]	2.03E-20	0.99 [0.96-1.01]	1.38E-01	0.97 [0.93-1.0]	1.76E-02
ffqvyam	Subject's average consumption of yams or sweet potatoes (1/2 cup) in the last year	1.02 [1.01-1.03]	1.93E-08	1.0 [0.97-1.04]	7.55E-01	1.01 [0.95-1.07]	7.12E-01
ffqwhitbrd	Subject's average consumption of white bread, including pita bread (slice), in the last year	0.99 [0.99-1.0]	1.93E-05	0.99 [0.97-1.01]	5.12E-02	0.99 [0.96-1.03]	5.36E-01
frybutter	Subject uses real butter for frying or sautéing at home	0.98 [0.96-1.0]	1.35E-02	1.01 [0.94-1.09]	7.29E-01	0.91 [0.78-1.05]	7.58E-02
frylard	Subject uses lard for frying or sautéing at home	0.92 [0.84-1.02]	1.99E-02	1.09 [0.78-1.47]	4.05E-01	1.06 [0.47-1.71]	7.68E-01
frymarg	Subject uses real butter for frying or sautéing at home	1.01 [0.98-1.04]	2.63E-01	0.94 [0.85-1.03]	7.56E-02	1.06 [0.9-1.24]	2.91E-01
fryvegoil	Subject uses margarine for frying or sautéing at home	1.03 [1.01-1.06]	2.57E-05	1.05 [0.98-1.14]	5.10E-02	1.06 [0.94-1.22]	1.96E-01
fryvegshort	Subject uses vegetable oil for frying or sautéing at home	1.0 [0.96-1.05]	7.80E-01	0.9 [0.76-1.05]	6.19E-02	0.95 [0.7-1.21]	6.03E-01
vita	Subject regularly takes Vitamin A	0.97 [0.93-1.01]	6.06E-02	1.05 [0.92-1.19]	3.15E-01	0.9 [0.71-1.11]	2.05E-01
vitamt	Number of multi-vitamins subject takes per week	0.95 [0.93-0.97]	3.51E-15	0.94 [0.89-1.01]	8.97E-03	0.87 [0.79-0.98]	4.87E-04

vitb6	Subject regularly takes Vitamin B6	1.0 [0.97-1.03]	9.94E-01	1.04 [0.93-1.16]	4.04E-01	0.95 [0.76-1.16]	5.12E-01
vitbcom	Subject regularly takes B-Complex vitamin	0.96 [0.94-0.99]	4.07E-04	0.92 [0.84-1.02]	2.63E-02	0.88 [0.72-1.04]	5.10E-02
vitbetac	Subject regularly takes beta-carotene	0.96 [0.89-1.05]	2.12E-01	1.07 [0.8-1.34]	4.94E-01	0.88 [0.47-1.32]	4.54E-01
vitc	Subject regularly takes Vitamin C	0.96 [0.94-0.99]	2.74E-05	1.04 [0.96-1.13]	1.71E-01	0.96 [0.81-1.11]	4.00E-01
vitca	Subject regularly takes Calcium	1.15 [1.13-1.18]	2.36E-56	2.11 [1.97-2.27]	2.21E-177	1.89 [1.67-2.16]	2.39E-43
vitcod	Subject regularly takes cod liver oil	1.0 [0.95-1.05]	9.31E-01	0.9 [0.76-1.06]	8.12E-02	0.91 [0.65-1.2]	3.63E-01
vitcop	Subject regularly takes copper	0.93 [0.85-1.02]	3.11E-02	0.96 [0.7-1.25]	7.00E-01	0.78 [0.4-1.23]	2.02E-01
vitd	Subject regularly takes Vitamin D	1.03 [1.01-1.05]	2.37E-05	1.27 [1.19-1.36]	3.90E-22	1.11 [0.98-1.26]	2.27E-02
vite	Subject regularly takes Vitamin E	0.95 [0.92-0.98]	1.44E-06	0.93 [0.84-1.02]	5.84E-02	0.91 [0.75-1.09]	1.40E-01
vitfa	Subject regularly takes folic acid	0.92 [0.89-0.96]	2.35E-08	0.98 [0.86-1.12]	6.72E-01	0.89 [0.7-1.11]	1.88E-01
vitiod	Subject regularly takes iodine	0.97 [0.89-1.05]	3.49E-01	1.19 [0.89-1.52]	7.12E-02	0.96 [0.5-1.49]	8.17E-01
vitiron	Subject regularly takes Iron	1.0 [0.97-1.03]	8.77E-01	1.03 [0.92-1.15]	3.99E-01	1.06 [0.86-1.27]	4.22E-01
vitmag	Subject regularly takes magnesium	0.93 [0.9-0.97]	2.21E-08	1.03 [0.91-1.15]	5.55E-01	0.97 [0.77-1.19]	6.85E-01
vitmetcl	Subject regularly takes Metamucil	1.0 [0.95-1.04]	7.80E-01	0.83 [0.69-0.97]	2.23E-03	0.79 [0.58-1.0]	1.98E-02
vitmv	Subject currently takes multi-vitamins	0.98 [0.96-1.01]	3.86E-02	0.87 [0.81-0.93]	7.47E-08	0.81 [0.71-0.93]	1.05E-05
vitnia	Subject regularly takes niacin	0.95 [0.9-0.99]	8.58E-04	0.93 [0.79-1.08]	1.79E-01	0.95 [0.7-1.23]	6.25E-01
vitomg3	Subject regularly takes Omega-3 fatty acid	0.98 [0.95-1.0]	1.42E-02	0.93 [0.85-1.01]	3.00E-02	0.82 [0.69-0.96]	1.11E-03
vitoth	Subject regularly takes other vitamins or supplements	0.98 [0.95-1.01]	7.92E-02	0.89 [0.8-0.97]	9.33E-04	1.12 [0.95-1.31]	5.62E-02
vitsel	Subject regularly takes Selenium	1.03 [0.97-1.09]	1.87E-01	1.29 [1.1-1.53]	2.32E-05	1.01 [0.7-1.34]	9.48E-01
vityrs	Number of years subject has taken multi-vitamins	0.95 [0.94-0.97]	1.80E-22	0.84 [0.81-0.88]	1.61E-24	0.83 [0.77-0.9]	3.70E-10
vitzinc	Subject regularly takes Zinc	0.93 [0.9-0.97]	7.25E-06	0.97 [0.84-1.1]	5.26E-01	0.96 [0.75-1.21]	6.31E-01

Supplemental Table 5: Exploratory univariable analysis of 126 baseline diet questions and association with three PCa clinical endpoints. Cox proportional hazards model results from association with age at prostate cancer, metastatic prostate cancer (nodal or distant) and death from prostate cancer. Hazard ratios (HR) are calculated per unit. Answers for average consumption in the last year were on a 9-point scale (Never/less than once a month, 1-3 times per month, once a week, 2-4 per week, 5-6 per week, once a day, 2-3 per day, 4-5 per day 6+ per day). *P*-values reported are from univariable models for each variable. No correction for multiple comparisons was applied for this exploratory analysis. Results should be interpreted cautiously.

Supplemental Figure 1: Healthy Lifestyle Score (HLS) distribution in self-reported race/ethnicity groups. HLS was calculated with three criteria: BMI ≤ 30, not a current smoker and vigorous physical activity ≥ 2 days per week. N, indicates the total number of participants with each score. One-Way ANOVA for HLS score, $p = 7.75\text{E-}10$, df = 3.

Supplemental Figure 2. Million Veteran Program (MVP) Cause-specific Cumulative Incidence of metastatic prostate cancer based on Healthy Lifestyle for participants with high genetic risk. Cause-specific cumulative incidence of metastatic prostate cancer within, stratified by HLS scores 0-1 and 3 for, for **(A)** all participants with HLS and genetic information, and **(B)** PHS290 80th percentile only.